OTC Markets OTCPK - Delayed Quote USD

Oncotelic Therapeutics, Inc. (OTLC)

0.0650

0.0000

(0.00%)

At close: May 30 at 9:30:01 AM EDT

Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm

AGOURA HILLS, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC), a biotechnology company focused on nanomedicine and RNA-based therapeutics, announced today that its Chairman and CEO, Dr. Vuong Trieu, will deliver a keynote presentation at the 21st Annual Congress of International Drug Discovery Science & Technology (IDDST-Europe), scheduled for June 18-20, 2025, in Stockholm, Sweden. Dr. Trieu's presentation, titled " Deciparticles: Novel Sub-20 nm Nanoparticl

GlobeNewswire last month

OTLC
0.00%
Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023

AGOURA HILLS, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, pancreatic ductal adenocarcinoma (“PDAC”), diffuse intrinsic pontine glioma (“DIPG”), and various other cancers, today announced its financial results for the fiscal year ended December 31, 2024 (“FY 2024”), as compared to the fiscal year ended December 31, 2023 (“FY 2023”)

GlobeNewswire last month

OTLC
0.00%
Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI

AGOURA HILLS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic,” the “Company,” or “We”), a leader in RNA-based therapeutics, today announced the publication of its latest research paper, titled, “Positive Prognostic Overall Survival Impacts of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients.” The paper, authored by Sanjive Qazi, Michael Potts, Scott Myers, Stephen Richardson, and Vuong Trieu, is available online at: https://www.mdpi.com/2

GlobeNewswire last month

OTLC
0.00%
Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference

AGOURA HILLS, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), ”), a leader in RNA-based therapeutics, announced today the successful completion of a Phase 1 clinical trial evaluating OT-101, in combination with IL-2 for advanced or metastatic solid tumors. These results set the stage for new studies that combine OT-101,an antisense therapeutic targeting Transforming Growth Factor Beta 2 (TGFβ2), with checkpoint in

GlobeNewswire 2 months ago

OTLC
0.00%
Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon

AGOURA HILLS, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC). Oncotelic Therapeutics Inc., a leader in RNA-based therapeutics, including its subsidiaries (“Oncotelic”) and including Sapu Bioscience, LLC (“SAPU”), a wholly owned subsidiary of GMP Biotechnology Limited in which Oncotelic is a 45% owner, is pleased to announce a strategic partnership with Shanghai Medicilon Inc. (“Medicilon”) (stock code: 688202.SH). Through this collaboration, Oncotelic and SAP

GlobeNewswire 3 months ago

OTLC
0.00%
Oncotelic CEO Vuong Trieu to Present Groundbreaking Research on Transforming Growth Factor Beta 2 (TGFB2) at SWCR 2025 Conference

AGOURA HILLS, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC). Oncotelic Therapeutics, a leader in RNA-based therapeutics, is pleased to announce that Vuong Trieu, Ph.D., Chairman & CEO, will be delivering a featured presentation at the SWCR 2025 Conference on March 24th. His talk will highlight the central role of Transforming Growth Factor Beta 2 (TGFB2) in the convergence of disease pathways spanning cancer, lupus, and aging, as well as its potential as a th

GlobeNewswire 3 months ago

OTLC
0.00%
Oncotelic Therapeutics Implements PDAOAI Platform

AGOURA HILLS, Calif., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), today announced the implementation of its artificial intelligence (AI) platform PDAOAI. The platform is designed to streamline document search and analysis, to address the growing needs of knowledge-based industries including pharmaceutical and biotechnology. We have been enhancing the capabilities of the platform over the past one year. The platform wil

GlobeNewswire 4 months ago

OTLC
0.00%
ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024

AGOURA HILLS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at SITC 2024. Dr. Cynthia Lee, VP of R&D will be presenting Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to: https://www.sitcancer.org/home. Dr. Lee has been leading our R&D programs for the past several years including the buildout of our GMP facility in San Diego. The presentations are: Abstract Number 198: TGFB2 mRNA levels prognost

GlobeNewswire 6 months ago

OTLC
0.00%
ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS

AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that pancreatic cancer patients with high expression levels of either TGFB2, IRF9, or IFI27 showed improvement of median overall survival from 16-20 months to 72 months for patients with low levels of expression for both TGFB2 and either IRF9 or IFI27 validating that knockdown of IRF9 and IFI27 as therapeutic targe

GlobeNewswire 6 months ago

OTLC
0.00%
ONCOTELIC PRESENTATION AT PRECISION IN DRUG DISCOVERY & PRECLINICAL SUMMIT SAN DIEGO 2024

AGOURA HILLS, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Precision in Drug Discovery & Preclinical Summit. Dr. Wen-Han Chang, Nanomedicine Sr. Manager, and Dr. Tara Zand, Research Scientist, presented Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to: https://events.precision-globe.com/single-event/precision-drug-discovery-preclinical-summit-san-diego##. Dr. Chang and Dr. Zand are experienc

GlobeNewswire 7 months ago

OTLC
0.00%
Product Manager Scott Myers to Present at 2nd Global Summit on Artificial Intelligence

AGOURA HILLS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today that Product Manager Scott Myers, working through GMP Biotechnology Limited, our 45% Joint Venture with Dragon Capital Limited, will be presenting at the 2nd Global Summit on Artificial Intelligence. The summit, which is being hosted digitally, is centered on the theme “Pioneering the New Era: Advancing Global Development through Artifici

GlobeNewswire 9 months ago

OTLC
0.00%
ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY

AGOURA HILLS, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will speak at the 20th Annual Congress of International Drug Discovery Science & Technology (IDDST) (Europe), June 17-19, 2024 at Budapest, Hungary. Title: TGFB2 therapeutic for the treatment of CRC, GBM, and PDAC Anirudh Kolanu, K. Khuranu, A. Mehta, T. Sanil1, G. Trieu, and Dr. Vuong Trieu* Abstract: OT-101, an antisense against TGFB2, is being tested in pha

GlobeNewswire 11 months ago

OTLC
0.00%

Performance Overview

Return	OTLC	S&P 500 (^GSPC)
YTD	+62.50%	+0.51%
1-Year	+62.50%	+12.92%
3-Year	-71.74%	+42.17%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Oncotelic Therapeutics, Inc. (OTLC)

Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm

Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023

Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI

Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference

Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon

Oncotelic CEO Vuong Trieu to Present Groundbreaking Research on Transforming Growth Factor Beta 2 (TGFB2) at SWCR 2025 Conference

Oncotelic Therapeutics Implements PDAOAI Platform

ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024

ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS

ONCOTELIC PRESENTATION AT PRECISION IN DRUG DISCOVERY & PRECLINICAL SUMMIT SAN DIEGO 2024

Product Manager Scott Myers to Present at 2nd Global Summit on Artificial Intelligence

ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY

Performance Overview